 |
|
|
| |
Entecavir (ETV) Therapy in Chronic Hepatitis B Patients Previously Treated with Adefovir (ADV) with Incomplete Response On-Treatment or Relapse Off-Treatment
|
| |
| |
Digestive Disease Week 2009 McCormick Place, Chicago Illinois May 30-June 4, 2009
Reported by Jules Levin
Nancy Leung1, Ching-Lung Lai2, Richard Elion3, Morris Sherman4, Hie-Won Hann5, DJ Lorne Tyrrell6, Chao Wei Hsu7, Chee-Kiat Tan8, Cheng-Yuan Peng9, Kim Mencarini10, Hui Zhang10, Uchenna Iloeje10 and Bruce Kreter11
1Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China; 2Department of Medicine, Queen Mary's Hospital, University of Hong Kong, Hong Kong, China; 3Whitman-Walker Clinic, Washington, WA, USA; 4Toronto General Hospital, Toronto, ON, Canada; 5Liver Disease Prevention Center, Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 6Health Sciences Center, Edmonton, AB, Canada; 7Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan; 8Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore; 9China Medical University Hospital, Taichung, Taiwan; 10Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA; 11Research and Development, Bristol-Myers Squibb Company, Princeton, NJ, USA
Disclosures
Ching-Lung Lai - Global Advisory Board: Bristol-Myers Squibb; Consulting and Speaking: Bristol-Myers Squibb. Richard Elion - Grants: Bristol-Myers Squibb, Gilead, Tibotec, GlaxoSmithKline and Taimed; Advisory: Bristol Myers-Squibb, Gilead, Tibotec, GlaxoSmithKline and Taimed. Morris Sherman - Speaker/Advisor: Bristol-Myers Squibb and Gilead. Hie-Won Hann - Grant/Research Support: Bristol-Myers Squibb, Gilead and Novartis; Speakers Bureau: Bristol-Myers Squibb, Gilead, Novartis and GlaxoSmithKline. DJ Lorne Tyrrell
- Research Support: GlaxoSmithKline. Kim Mencarini, Hui Zhang, Uchenna Iloeje and Bruce Kreter - Bristol-Myers Squibb employees. The following people have nothing to disclose: Nancy Leung, Chao Wei Hsu, Chee-Kiat Tan and Cheng-Yuan Peng.
|
| |
|
|
|
|
|
